• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current therapeutic research, clinical and experimental. >Effects of Photodynamic Therapy With Verteporfin for the Treatment of Chronic Central Serous Chorioretinopathy:An Uncontrolled, Open-Label, Observational Study
【24h】

Effects of Photodynamic Therapy With Verteporfin for the Treatment of Chronic Central Serous Chorioretinopathy:An Uncontrolled, Open-Label, Observational Study

机译：Verteporfin的光动力疗法治疗慢性中央性浆液性脉络膜视网膜病变的效果：不受控制的开放标签观察性研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Central serous chorioretinopathy is an idiopathic disorder that leads to serous neurosensory retinal detachment. The disorder is usually self-limited and resolves spontaneously; however, sometimes neurosensory retinal detachment persists. This form of the disorder is called chronic central serous chorioretinopathy (CCSC).OBJECTIVE: The aim of this study was to assess the effects of photodynamic therapy (PDT) on visual acuity with full-dose verteporfm for CCSC.METHODS: The eyes of patients with CCSC were included in the study. Ophthalmic examination including best-corrected visual acuity (BCVA), fundus examination, fluorescein angiography, and optical coherence tomography was performed before treatment and at 1, 3, 6, 9, and 12 months. PDT with full-dose verteporfin (6 mg/m2 of body surface area) was applied only to areas of active leakage. BCVA was converted to a log of the minimum angle of resolution (logMAR) equivalent for statistical analysis. Central foveal thickness and BCVA between baseline and follow-up were compared.RESULTS: Seventeen eyes of 16 patients (13 males, 3 females; mean [SD} age, 39-75 [7.51} years; mean duration of follow-up, 13.06 [1.82] months) were used in the study. The mean (SEM) logMAR BCVA was 0.26 (0.07) at baseline and 0.04 (0.02) at 12 months. Mean logMAR BCVA values at baseline (0.259) and after treatment (0.112, 0.053, 0.047, 0.041, and 0.041 at 1, 3, 6, 9, and 12 months, respectively) differed significantly (P = 0.006, P = 0.005, P = 0.005, P = 0.005, and P = 0.005). There was a significant difference in the mean central foveal thickness at the final visit (169 mum) compared with the baseline value (383 mum; P < 0.001). BCVA decreased in one eye (20/20 vs 20/25) and persisted during follow-up; in the other 16 eyes, BCVA either increased (n = 10) or remained stable (n = 6).CONCLUSIONS: In this small, open-label study, patients with CCSC treated with a single course of PDT with full-dose verteporfin had significant improvement from baseline in BCVA and resolution of subretinal fluid accumulation and active leakage. Treatment was generally well tolerated, but one patient had worsening in BCVA.
机译：背景：中枢性浆液性脉络膜视网膜病变是一种特发性疾病，可导致浆液性神经感觉性视网膜脱离。这种疾病通常是自限性的，可以自发解决。然而，有时神经感觉性视网膜脱离仍然存在。这种疾病称为慢性中枢性浆液性脉络膜视网膜病变（CCSC）。目的：本研究的目的是评估光动力疗法（PDT）对全剂量Verteporfm治疗CCSC视力的影响。方法：患者的眼睛与CCSC一起被纳入研究。在治疗前和1、3、6、9和12个月进行眼科检查，包括最佳矫正视力（BCVA），眼底检查，荧光素血管造影和光学相干断层扫描。含全剂量维替泊芬的PDT（体表面积6 mg / m2）仅应用于主动渗漏区域。将BCVA转换为等效的最小分辨率对数（logMAR）对数进行统计分析。结果：比较了基线和随访之间中央凹的厚度和BCVA。结果：16例患者的17眼（男13例，女3例;平均[SD}年龄：39-75 [7.51}岁;平均随访时间13.06） [1.82]个月）用于研究。基线的平均（SEM）logMAR BCVA为0.26（0.07），而在12个月时为0.04（0.02）。基线（0.259）和治疗后（分别在1、3、6、9和12个月分别为0.112、0.053、0.047、0.041和0.041）的logMAR BCVA平均平均值有显着差异（P = 0.006，P = 0.005，P = 0.005，P = 0.005和P = 0.005）。与基线值（383 mum，P <0.001）相比，末次访视的平均中央凹中心厚度（169 mum）有显着差异。一只眼睛的BCVA降低（20/20对20/25），并在随访期间持续存在;在另外16只眼中，BCVA升高（n = 10）或保持稳定（n = 6）。结论：在这项小型的开放标签研究中，接受单疗程PDT全剂量维替泊芬治疗的CCSC患者与BCVA的基线相比有了显着改善，并解决了视网膜下积液和主动渗漏。治疗通常耐受良好，但是一名患者的BCVA恶化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号